Adverse drug reactions in high-risk pregnant women: A prospective study

Oliveira-Filho, Alfredo Dias de; Vieira, Antonio Emanuel Soares; Silva, Roberta Cruz da; Neves, Sabrina Joany Felizardo; Gama, Thiago Antonio Barros; Lima, Ryane Vieira; Oliveira, Wlisses Ramon; Dias, Júlia Maria Gonçalves

doi:10.1016/j.jsps.2017.01.005

Cited by 12 publications

(16 citation statements)

References 34 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a recent study, a recurrent clinically manifested DDI of methyldopa with ferrous sulfate, in which one drug made the other less effective, resulted in an increase in systolic blood pressure (BP) in all high-risk pregnant women who were evaluated. After ferrous sulfate was discontinued, a reduction was noted in the BP levels of patients [14].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis

Santos¹,

Macieira²,

Alves³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

This review aims to determine the prevalence of clinically manifested drug-drug interactions (DDIs) in hospitalized patients. Methods PubMed, Scopus, Embase, Web of Science, and Lilacs databases were used to identify articles published before June 2019 that met specific inclusion criteria. The search strategy was developed using both controlled and uncontrolled vocabulary related to the following domains: "drug interactions," "clinically relevant," and "hospital." In this review, we discuss original observational studies that detected DDIs in the hospital setting, studies that provided enough data to allow us to calculate the prevalence of clinically manifested DDIs, and studies that described the drugs prescribed or provided DDI adverse reaction reports, published in either English, Portuguese, or Spanish. Results From the initial 5,999 articles identified, 10 met the inclusion criteria. The pooled prevalence of clinically manifested DDIs was 9.2% (CI 95% 4.0-19.7). The mean number of medications per patient reported in six studies ranged from 4.0 to 9.0, with an overall average of 5.47 ± 1.77 drugs per patient. The quality of the included studies was moderate. The main methods used to identify clinically manifested DDIs were evaluating medical records and ward visits (n = 7). Micromedex® (27.7%) and Lexi-Comp® (27.7%) online reference databases were commonly used to detect DDIs and none of the studies evaluated used more than one database for this purpose.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis

Santos¹,

Macieira²,

Alves³

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Published studies on ADR in pregnancy have shown very different prevalences among them, with estimates ranging between 0.3 and 20.0% [14, 16]. The only Brazilian work on the topic [17] reported that 8.8% women from a sample of 294 high-risk hospitalized pregnant women suffered an ADR. Hernández-Hernández et al [16], in a Mexican cohort of 207 pregnant women, observed ADR in 12.1%.…”

Section: Discussionmentioning

confidence: 99%

“…A few studies have estimated the incidence of ADR during pregnancy at around 10% [14, 16, 17], but in general they were based on small samples and the identification of ADR was not through active search. In addition, the drugs involved and the clinical manifestations of ADR have not been adequately described and, to the best of our knowledge, no studies have yet attempted to identify risk factors for the occurrence of ADR.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and profile of adverse drug reactions in high-risk pregnancy: a cohort study

Silva

Fernandes

Pessoa

et al. 2019

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

Background C ommonly used drugs in pregnant women include antihypertensives, hypoglycemic agents, analgesics, antimicrobials, antiemetics and antispasmodics but the use of medicines during pregnancy, especially in high-risk pregnancy, may be associated with high risk of adverse drug reactions (ADR). The objective of this study was to determine the risk of an adverse drug reaction in hospitalized high-risk pregnant women and the factors associated with their occurrence. Methods The study received IRB approval and all patients gave written informed consent. Observational cohort study conducted from September 2015 to November 2016 in 1070 pregnant women consecutively admitted to the high risk sector of the University Maternity Januário Cicco in Brazil. ADR were detected through daily active search. Risk factors for the occurrence of ADR were determined using multivariate logistic regression. Results The mean age of the study population was 26.2 ± 7.2 years and gestational age was 31.2 ± 7.2 weeks. The average number of previous pregnancies was 2.4 ± 1.8 and 46.4% reported cases of previous abortion/miscarriage. ADR were observed in 10.7% of women. The main medicines involved, with the incidence rate of ADR per 100 prescriptions of the drug (IR), were parenteral scopolamine (IR 14.9%), methyldopa (IR 15.9%), insulin (IR 8.46%), oral scopolamine (IR 3.58%), captopril (IR 2.38%) and ceftriaxone (IR 18.4%). Multivariate analysis showed that only gestational age in weeks (odds-ratio 0.97, 95% confidence interval 0.95–0.98) was related to the occurrence of adverse reactions. Conclusion Lower gestational age is a risk factor for high-risk pregnant women, increasing the likelihood of adverse reactions, with parenteral medications being those that have the highest potential risk of harm. Electronic supplementary material The online version of this article (10.1186/s12884-019-2321-8) contains supplementary material, which is available to authorized users.

show abstract

“…Günümüzde birçok ilacın potansiyel teratojenik etkisi henüz ortaya konulamadığı için gebelikte ilaç kullanımının dikkatlice ele alınması gerekmektedir (4). Amerikan Gıda ve İlaç Dairesi (FDA) tarafından 2003-2012 yılları arasında onaylanan 213 yeni ilacın sadece %5'inin gebelikte güvenli olarak kullanılabileceği bildirilmiş olup (5) hala gebelikte birçok ilacın güvenli olarak kullanılıp-kullanılmayacağı ile ilgili bilgilerin sınırlı kaldığı görülmektedir (6).…”

Section: Introductionunclassified

“…Gebelikte ilaç kullanımı durumunda hem annenin hem de fetüsün sağlığı ile ilgili soru ve kaygıların giderilmesi, hangi durumlarda ne tür ilaçların kullanılabileceği ile ilgili bilgilerin verilmesi ve ilaç kullanımı durumunda oluşabilecek risklerin değerlendirilmesinde sağlık profesyonellerine önemli görevler düşmektedir. Literatüre baktığımızda birçok çalışmada insan popülasyonları ve hastalar arasında akılcı ilaç kullanımı ve ilaç kullanım bilgisi gibi konular araştırılsa da insan hayatının en önemli dönemlerinden biri olan fetal yaşamda gebelerin ilaç kullanım durumuna yönelik literatür bilgisinin sınırlı kaldığı görülmektedir (1,2,4,5,6,13). Çalışma gebelerin ilaç kullanım durumu ve ilaç güvenliği bilgilerinin incelenmesi amacıyla yapılmıştır.…”

Section: Introductionunclassified

Gebeleri̇n İlaç Kullanim Durumu Ve Güvenli̇ İlaç Kullanimi Bi̇lgi̇leri̇ni̇n İncelenmesi̇

Çobanoğlu¹

2020

Journal of Anatolia Nursing and Health Sciences

View full text Add to dashboard Cite

Çalışma gebelerin ilaç kullanımı ile gebelikte ilaç kullanım durumları ve ilaç güvenliği bilgilerinin incelenmesi amacıyla yapıldı. Yöntem: Kesitsel ve tanımlayıcı tipteki çalışmanın örneklemini güç analizi sonucunda hesaplanan ve araştırma kriterlerine uyan 378 gebe kadın oluşturdu. Araştırma verileri araştırmacı tarafından literatür taranarak oluşturulan 19 sorudan oluşan bir form ile toplandı. Verilerin analizi SPSS 15.0 paket programı kullanılarak gerçekleştirildi. Araştırmanın yapılabilmesi için hem kurum izni hem de etik kurul izni alındı. Bulgular: Araştırma örneklemindeki gebe kadınların yaş ortalamasının 28.43±5.47 yıl olduğu, %52.4'ünün ilçede yaşadığı, %42.9'unun ortaöğrenim gördüğü saptandı. Gebe kadınların %90.2'sinin gebelikte ilaç kullandığı ve %77.8'inin vitamin/mineral ilaçları aldığı, %4'ünün ise hekim önerisi dışında ilaç kullandığı saptandı. Gebelerin %75.4'ünün ilaç kullanımı ile ilgili bilgi aldığı, bilgi alanların %44.4'ünün hekim tarafından, %16.7'sinin ebe/hemşire tarafından bilgilendirildiği ve %12.7'sinin internetten bilgi edindiği belirlendi. Sonuç: Çalışmada gebelerin gebelik sürecinde ilaç kullanım oranının oldukça yüksek olduğu (%90.2) en çok besin takviyesi olan vitamin ve mineral içeren ilaçları kullandıkları (%96.4'ünün hekim önerisi ile), gebelikte ilaç kullanımı ile bilgileri en sık hekimden aldıkları, internet kaynağı olarak güvenli ve bilimsel verileri içermeyen internet sitelerini kullandıkları saptandı.

show abstract

Adverse drug reactions in high-risk pregnant women: A prospective study

Abstract: Overall, ADRs were not common events among high-risk pregnant women and no adverse pregnancy outcomes following these events were observed.

Cited by 12 publications

References 34 publications

Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis

Prevalence of clinically manifested drug interactions in hospitalized patients: A systematic review and meta-analysis

Prevalence and profile of adverse drug reactions in high-risk pregnancy: a cohort study

Gebeleri̇n İlaç Kullanim Durumu Ve Güvenli̇ İlaç Kullanimi Bi̇lgi̇leri̇ni̇n İncelenmesi̇

Contact Info

Product

Resources

About